In patients with stroke or TIA and CYP2C19 loss-of-function alleles, ticagrelor vs. clopidogrel reduced 90-d stroke

Ann Intern Med. 2022 Mar;175(3):JC30. doi: 10.7326/J22-0008. Epub 2022 Mar 1.

Abstract

Wang Y, Meng X, Wang A, et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. N Engl J Med. 2021;385:2520-30. 34708996.

Publication types

  • Comment

MeSH terms

  • Alleles
  • Clopidogrel / therapeutic use
  • Cytochrome P-450 CYP2C19 / genetics
  • Humans
  • Ischemic Attack, Transient* / drug therapy
  • Ischemic Attack, Transient* / genetics
  • Platelet Aggregation Inhibitors / therapeutic use
  • Stroke* / drug therapy
  • Stroke* / genetics
  • Ticagrelor / therapeutic use

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Ticagrelor